166 related articles for article (PubMed ID: 24516101)
1. The noradrenergic component in tapentadol action counteracts μ-opioid receptor-mediated adverse effects on adult neurogenesis.
Meneghini V; Cuccurazzu B; Bortolotto V; Ramazzotti V; Ubezio F; Tzschentke TM; Canonico PL; Grilli M
Mol Pharmacol; 2014 May; 85(5):658-70. PubMed ID: 24516101
[TBL] [Abstract][Full Text] [Related]
2. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
[TBL] [Abstract][Full Text] [Related]
3. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
5. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
Kögel B; De Vry J; Tzschentke TM; Christoph T
Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
[TBL] [Abstract][Full Text] [Related]
6. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
7. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit.
Cowan A; Raffa RB; Tallarida CS; Tallarida RJ; Christoph T; Schröder W; Tzschentke TM
Eur J Pain; 2014 Sep; 18(8):1148-56. PubMed ID: 24574066
[TBL] [Abstract][Full Text] [Related]
8. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis.
Tzschentke TM; Folgering JH; Flik G; De Vry J
Neurosci Lett; 2012 Jan; 507(2):151-5. PubMed ID: 22197547
[TBL] [Abstract][Full Text] [Related]
9. Effect of tapentadol on neurons in the locus coeruleus.
Torres-Sanchez S; Alba-Delgado C; Llorca-Torralba M; Mico JA; Berrocoso E
Neuropharmacology; 2013 Sep; 72():250-8. PubMed ID: 23664814
[TBL] [Abstract][Full Text] [Related]
10. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
Gonçalves L; Friend LV; Dickenson AH
Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol for pain: a treatment evaluation.
Hartrick CT; Rodríguez Hernandez JR
Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
[TBL] [Abstract][Full Text] [Related]
12. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of tapentadol metabolites.
Terlinden R; Kogel BY; Englberger W; Tzschentke TM
Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
[TBL] [Abstract][Full Text] [Related]
15. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
[TBL] [Abstract][Full Text] [Related]
16. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.
Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX
Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607
[TBL] [Abstract][Full Text] [Related]
18. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
Tzschentke TM; Christoph T; Kögel BY
CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
[TBL] [Abstract][Full Text] [Related]
19. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
Christoph T; De Vry J; Tzschentke TM
Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
[TBL] [Abstract][Full Text] [Related]
20. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice.
Ramírez-Rodríguez G; Klempin F; Babu H; Benítez-King G; Kempermann G
Neuropsychopharmacology; 2009 Aug; 34(9):2180-91. PubMed ID: 19421166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
